CCN3 and prostate carcinoma: Additionally, prostate cancer-secreted CCN3 was shown to mediate RANK upregulation in osteoclast precursors via the FAK/AKT/mitogen-activated protein kinase 11 (p38)/NF-κB axis and, thus, promotes the RANKL-dependent osteoclastogenesis and tumor-induced osteolysis [112].